Acquisitions

Acquisitions completed from the 2023 financial year are distributed among the group’s business areas as follows:

Revaluation of liabilities for contingent considerations related to previous acquisitions in the Medtech Business Area has resulted in an income of SEK 7m. During the interim period, these have been reversed and reported in other operating income. Contingent consideration amounting to SEK 41m has been paid during the interim period regarding BioConnect, Funksjonsutstyr and O'Flynn, which were acquired in previous years.